

# 中国肿瘤生物治疗杂志

CHINESE J 0 |



首页 期刊概况 编委会 期刊内容 特邀审稿 投稿指南 出版发行

306~310.大规模平行测序技术筛选人肾细胞癌组织中差异表达microRNAs及其验证[J].翟庆娜,周亮,余振东,唐爱发,王勇,桂耀庭.中国肿瘤生物治疗杂志,2011,18(3)

#### 大规模平行测序技术筛选人肾细胞癌组织中差异表达microRNAs及其验证 点此下载全文

## 翟庆娜 周亮 余振东 唐爱发 王勇 桂耀庭

北京大学 深圳医院 检验科,广东 深圳518036;汕头大学医学院 临床检验诊断学教研室,广东 汕头 515031;北京大学 深圳医院 男性生殖与遗传学省重点实验室,广东 深圳518036;北京大学 深圳医院 男性生殖与遗传学省重点实验室,广东 深圳518036;北京大学 深圳医院 男性生殖与遗传学省重点实验室,广东 深圳518036;北京大学 深圳医院 男性生殖与遗传学省重点实验室,广东 深圳518036;北京大学 深圳医院 男性生殖与遗传学省重点实验室,广东 深圳518036

基金项目: 国家自然科学基金资助项目(No. 30900817);深港创新圈项目资助(No. ZYB200907080110A)

DOI:

#### 摘要:

目的:以大规模平行测序技术(massively parallel signature sequencing,MPSS)筛选人肾细胞癌(renal cell carcinoma,RCC)和癌旁组织中差异表达的microRNAs(miRNAs),并验证差异表达miRNAs之一的miR-660在人RCC中的表达。方法:MPSS检测10例RCC组织及相应癌旁组织中miRNAs的表达,筛选RCC组织中差异表达miRNAs。RT-PCR检测5例RCC与癌旁组织中miR-660的表达,qPCR检测40例RCC与癌旁组织中miR-660的表达。结果:MPSS结果显示,RCC组织中283个miRNAs表达下调,187个表达上调,其中miR-660在RCC组织中表达量是癌旁组织的17.5%。RT-PCR初步验证了此结果;qPCR验证结果显示,40例RCC组织中33例miR-660表达显著低于癌旁组织,RCC组织中miR-660平均表达量是癌旁的19 5%。结论:人RCC组织中283个miRNAs表达下调、187个上调。miR-660在RCC组织中低表达,有可能成为RCC诊断及治疗的新靶点。

#### 关键词: 肾细胞癌 microRNAs 大规模平行测序技术 miR-660

Massively parallel signature sequencing in screening differentially expressed microRNAs in human renal cell carcinoma tissues and their identification <u>Download Fulltext</u>

#### ZHAI Qing-na ZHOU Liang YU Zhen-dong TANG Ai-fa WANG Yong GUI Yao-ting

Department of Clinical Laboratory, Shenzhen Hospital of Peking University, Shenzhen 518036, Guangdong, China; Department of Clinical Laboratory Diagnostics, Shantou University Medical College, Shantou 515031, Guangdong, China; Key Laboratory of Male Reproductive Medicine and Genetics in Guangdong, Shenzhen Hospital of Peking University, Shenzhen 518036, Guangdong, China; Department of Clinical Laboratory, Shenzhen Hospital of Peking University, Shenzhen 518036, Guangdong, China; Key Laboratory of Male Reproductive Medicine and Genetics in Guangdong, Shenzhen Hospital of Peking University, Shenzhen 518036, Guangdong, China; Key Laboratory of Male Reproductive Medicine and Genetics in Guangdong, Shenzhen Hospital of Peking University, Shenzhen 518036, Guangdong, China; Key Laboratory of Male Reproductive Medicine and Genetics in Guangdong, Shenzhen Hospital of Peking University, Shenzhen 518036, Guangdong, China; Key Laboratory of Male Reproductive Medicine and Genetics in Guangdong, Shenzhen Hospital of Peking University, Shenzhen 518036, Guangdong, China; Key Laboratory of Male Reproductive Medicine and Genetics in Guangdong, Shenzhen Hospital of Peking University, Shenzhen 518036, Guangdong, China; Key Laboratory of Male Reproductive Medicine and Genetics in Guangdong, Shenzhen Hospital of Peking University, Shenzhen 518036, Guangdong, China; Key Laboratory of Male Reproductive Medicine and Genetics in Guangdong, Shenzhen Hospital of Peking University, Shenzhen 518036, Guangdong, China; Key Laboratory of Male Reproductive Medicine and Genetics in Guangdong, Shenzhen Hospital of Peking University, Shenzhen 518036, Guangdong, China; Key Laboratory of Male Reproductive Medicine and Genetics in Guangdong, Shenzhen Hospital of Peking University, Shenzhen 518036, Guangdong, China; Key Laboratory of Male Reproductive Medicine and Genetics in Guangdong, Shenzhen Hospital of Peking University, Shenzhen 518036, Guangdong, China; Key Laboratory of Male Reproductive Medicine and Genetics in Guangdong, Shenzhen Hospital of

Fund Project: Project supported by the National Natural Science Foundation of China (No. 900817), and the Shenzhen-HongKong Innovation Circle Project (No. ZYB200907080110A)

### Abstract:

Objective: To screen differentially expressed microRNAs (miRNAs) in tumor and the corresponding paracancerous tissues of renal cell carcinoma (RCC) by massively parallel signature sequencing (MPSS), and to identify the expression of miR-660 in RCC. Methods: The expression of miRNAs in tumor and the corresponding paracancerous tissues of 10 RCC patients was examined by MPSS, and the differentially expressed miRNAs were screened. Expression of miR-660 in tumor tissues of 5 patients and the paracancerous tissues of 40 RCC patients were further examined by RT-PCR and qPCR, respectively. Results: The MPSS results showed that 283 miRNAs were upregulated and 187 were down-regulated in RCC tissues, and the expression level of miR-660 in RCC tissues was only 19.5% of that in the paracancerous tissues. The MPSS results were primarily confirmed by RT-PCR, and qPCR results further showed that miR-660 expression in 34 of 40 RCC tissues was significantly lower than that in the paracancerous tissues, with the average level being only 11.7% of that in the paracancerous tissues. Conclusion: A total of 283 miRNAs are up-regulated and 187 down-regulated in RCC tissues; and miR-660 is lowly expressed in RCC, which may be a new target for the diagnosis and treatment of RCC.

Keywords: renal cell carcinoma microRNA massively parallel signature sequencing (MPSS) miR-660

查看全文 查看/发表评论 下载PDF阅读器

Copyright © Biother.Org™ All Rights Reserved 主管单位:中国科学技术协会 主办单位:中国免疫学会、中国抗癌学会

地址: 上海市杨浦区翔殷路800号 邮政编码: 200433 京ICP备06011393号-2

本系统由北京勤云科技发展有限公司设计